Clinical Trial Update: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of Phase 1/Phase 2 studies of veliparib as monotherapy in relapsed BRCA-mutated ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Veliparib (veliparib)

Snippet

Sponsor: Vejle Hospital | Conditions: Recurrent, Epithelial Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED